NKGen Biotech, Inc. (NKGN)

NASDAQ: NKGN · IEX Real-Time Price · USD

1.190

+0.080 (7.21%)

At close: Jul 19, 2024, 4:00 PM

1.188

-0.002 (-0.17%)

Pre-market: Jul 22, 2024, 9:03 AM EDT

NKGen Biotech Employees

NKGen Biotech had 63 employees as of December 31, 2023.

Employees

63

Change

n/a

Growth

n/a

Revenue / Employee

n/a

Profits / Employee

-$1,270,063

Market Cap

30.67M

Employees Chart

Employees History

Date	Employees	Change	Growth
Dec 31, 2023	63	-	-

Related Stocks

Company Name	Employees
CareCloud	3,600
Evogene	142
Spectral AI	78
Equillium	44
MiNK Therapeutics	31
Longeveron	24
Lipocine	17
Reviva Pharmaceuticals Holdings	15

Employee Rankings

NKGN News

4 days ago - NKGen Biotech to Present New Positive SNK01 Clinical Trial Biomarker Data at the 2024 Alzheimer's Association International Conference - GlobeNewsWire
7 days ago - NKGen Biotech Appoints Dr. Marco Gottardis to its Board of Directors - GlobeNewsWire
5 weeks ago - NKGen Biotech Presents Updated Phase 1 Data on SNK02 Allogeneic NK Cell Therapy for Solid Tumors at the 6th Annual Allogeneic Cell Therapies Summit 2024 - GlobeNewsWire
7 weeks ago - NKGen Biotech To Present Updated Phase 1 Data on SNK02 Allogeneic NK Cell Therapy in Solid Tumors at the 6th Annual Allogeneic Cell Therapies Summit 2024 - GlobeNewsWire
2 months ago - NKGen Biotech Publishes Phase 1 Interim Analysis Results of SNK02 Allogeneic NK Cell Therapy in Advanced Solid Tumors at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting - GlobeNewsWire
2 months ago - NKGen Biotech's SNK01 NK Cell Therapy Cleared to Start Phase 2 Clinical Trial in Alzheimer's Disease - GlobeNewsWire
2 months ago - NKGen Biotech Announces Upcoming Presentation on Autologous NK Cell Therapy at the 5th International Cell & Gene Therapy China Summit & Exhibition - GlobeNewsWire
3 months ago - NKGen Biotech Announces FDA Clearance of Investigational New Drug (IND) Application for SNK01 NK Cell Therapy in Parkinson's Disease - GlobeNewsWire